Takeda Pharmaceutical Company Limited (TKPHF)
| Market Cap | 42.05B |
| Revenue (ttm) | 31.73B |
| Net Income (ttm) | 2.02B |
| Shares Out | n/a |
| EPS (ttm) | 1.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 305 |
| Open | 25.55 |
| Previous Close | 25.91 |
| Day's Range | 25.55 - 25.55 |
| 52-Week Range | 23.80 - 30.90 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About TKPHF
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]
Full Company ProfileFinancial Performance
In 2023, TKPHF's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.
Financial numbers in JPY Financial StatementsNews
Takeda Pharmaceutical Co Ltd (TAK) Shares Gap Down to $13.745 on Nov 6
Takeda Pharmaceutical Co Ltd (TAK) Shares Gap Down to $13.745 on Nov 6
Takeda Pharmaceutical Company Limited 2025 Q2 - Results - Earnings Call Presentation
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President an...
Takeda Raises Full-Year Outlook on Cost Cuts, Restructuring Plan
Takeda Pharmaceutical Co. raised its full-year forecast for operating income by 18% to ¥265 billion ($1.7 billion) after a bumper second quarter, helped by key drug sales as well as cost savings in No...
Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments
Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs.
Takeda Pharmaceutical reports H1 results, revises FY forecast
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in it...
Takeda Pharmaceutical FQ2 Earnings Preview
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) and Boston Medical Center (BMC) today announced a new collaboration focused on identifying innovative solutions that can reduce...
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehe...
Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical
Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector
Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delv...
Takeda Pharmaceuticals: An Interesting Option For Income Investors
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an ext...
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry compar...
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undert...
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaborati...
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and m...
In-Depth Analysis: Eli Lilly Versus Competitors In Pharmaceuticals Industry
In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we...
Abbott India partners with Takeda Pharmaceuticals to launch Vonefi
Abbott India Limited has announced the signing of a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited to market and distribute Vonoprazan in India under the brand name...
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-...
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partner...
Lupin signs non-exclusive patent license agreement with Takeda to commercialize Vonoprazan in India
Lupin Limited has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan Tablets in India. Under this agreement, Lupin will market...
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we...
U.S. allows ADHD drugmaker to increase production limit to ease ongoing shortage
The Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions to ease shortages.